The selective oestrogen receptor modulation: evolution and clinical applications
- 24 December 1999
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 48 (6) , 785-792
- https://doi.org/10.1046/j.1365-2125.1999.00089.x
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- A pharmacological review of raloxifeneJournal of Bone and Mineral Metabolism, 1996
- Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women.Journal of Clinical Investigation, 1996
- Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized ratsJournal of Bone and Mineral Research, 1994
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987
- 243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma modelJournal of Steroid Biochemistry, 1974